Dudley Dawn M, Wentzel Jennifer L, Lalonde Matthew S, Veazey Ronald S, Arts Eric J
Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
J Virol. 2009 May;83(10):5067-76. doi: 10.1128/JVI.00055-09. Epub 2009 Mar 11.
PSC-RANTES binds to CCR5, inhibits human immunodeficiency virus type 1 (HIV-1) entry, and has been shown as a vaginal microbicide to protect rhesus macaques from a simian-human immunodeficiency virus chimera (SHIV(SF162-p3)) infection in a dose-dependent manner. In this study, env gene sequences from SHIV(SF162-p3)-infected rhesus macaques treated with PSC-RANTES were analyzed for possible drug escape variants. Two specific mutations located in the V3 region of gp120 (K315R) and C-helical domain of gp41 (N640D) were identified in a macaque (m584) pretreated with a 100 microM dose of PSC-RANTES. These two env mutations were found throughout infection (through week 77) but were found at only low frequencies in the inoculating SHIV(SF162-p3) stock and in the other SHIV(SF162-p3)-infected macaques. HIV-1 env genes from macaque m584 (env(m584)) and from inoculating SHIV(SF162-p3) (env(p3)) were cloned into an HIV-1 backbone. Increases in 50% inhibitory concentrations to PSC-RANTES with env(m584) were modest (sevenfold) and most pronounced in cells expressing rhesus macaque CCR5 as compared to human CCR5. Nonetheless, virus harboring env(m584), unlike inoculating virus env(p3), could replicate even at the highest tissue culture PSC-RANTES concentrations (100 nM). Dual-virus competitions revealed a dramatic increase in fitness of chimeric virus containing env(m584) (K315R/N640D) over that containing env(p3), but again, only in rhesus CCR5-expressing cells. This study is the first to describe the immediate selection and infection of a drug-resistant SHIV variant in the face of a protective vaginal microbicide, PSC-RANTES. This rhesus CCR5-specific/PSC- RANTES resistance selection is particularly alarming given the relative homogeneity of the SHIV(SF162-p3) stock compared to the potential exposure to a heterogeneous HIV-1 population in human transmission.
PSC-RANTES可与CCR5结合,抑制1型人类免疫缺陷病毒(HIV-1)进入细胞,并且已被证明是一种阴道杀菌剂,能够以剂量依赖的方式保护恒河猴免受猿猴-人类免疫缺陷病毒嵌合体(SHIV(SF162-p3))感染。在本研究中,分析了用PSC-RANTES治疗的感染SHIV(SF162-p3)的恒河猴的env基因序列,以寻找可能的耐药变异体。在一只预先接受100微摩尔剂量PSC-RANTES治疗的恒河猴(m584)中,在gp120的V3区域(K315R)和gp41的C螺旋结构域(N640D)发现了两个特异性突变。在整个感染过程(直至第77周)中均发现了这两个env突变,但在接种的SHIV(SF162-p3)毒株以及其他感染SHIV(SF162-p3)的恒河猴中,它们仅以低频率出现。将恒河猴m584的HIV-1 env基因(env(m584))和接种的SHIV(SF162-p3)的env基因(env(p3))克隆到HIV-1骨架中。与人类CCR5相比,env(m584)对PSC-RANTES的50%抑制浓度的增加幅度较小(7倍),且在表达恒河猴CCR5的细胞中最为明显。尽管如此,携带env(m584)的病毒与接种病毒env(p3)不同,即使在组织培养中PSC-RANTES的最高浓度(100纳摩尔)下也能复制。双病毒竞争实验表明,含有env(m584)(K315R/N640D)的嵌合病毒的适应性比含有env(p3)的嵌合病毒显著增加,但同样仅在表达恒河猴CCR5的细胞中如此。本研究首次描述了在存在保护性阴道杀菌剂PSC-RANTES的情况下,耐药性SHIV变异体的即时选择和感染情况。鉴于与人类传播中潜在接触的异质性HIV-1群体相比,SHIV(SF162-p3)毒株的相对同质性,这种恒河猴CCR5特异性/PSC-RANTES耐药性选择尤其令人担忧。